ez2go Laxative Bisacodyl

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ez2go Laxative Bisacodyl
Generic name
BISACODYL
Manufacturer
Valley Medical Products, LLC
Product type
HUMAN OTC DRUG
SPL set ID
e7bf28c4-58d9-4259-925c-16fbd45c66d3
SPL ID
494cc23a-ef5b-26cd-e063-6294a90a4f15
Version
1
Effective date
2026-01-26
Source export date
2026-09-28
Source partition
4
Source file
https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-09-28/c7ca0b7091cdaeab3f27713a6eef00adcf8fe722383633ddce61531b4c840544/drug-label-0004-of-0014.json.zip
Source manifest SHA-256
cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run
20260929T050834Z
Imported at
2026-09-29 05:25:48
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings Do not use: if you cannot swallow without chewing Ask a doctor before use if you have Stomach pain, nausea or vomiting A sudden change in bowel habits that lasts more than 2 weeks When using this product Do not chew or crush tablet(s) Do not use within 1 hour after taking an antacid or milk you may have stomach discomfort, faintness & cramps Stop use and ask a doctor if You have rectal bleeding or fail to have a bowel movement after use of a laxative. These could be signs of a serious condition You need to use a laxative for more than 1 week If pregnant or breast-feeding, ask a health professional before use Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.